

NEWSLETTER

CHEMICAL & PHARMACEUTICAL

20 - 26 July 2026



India's Ban on Sulfur Exports Triggers Price Hikes Across Chinese Refineries

India has officially banned all sulfur exports to prioritize its domestic market, sparking global supply concerns. In response to tightening overseas availability, China's sulfur market surged on July 15. Refineries in Shandong raised factory prices by up to 200 yuan (€ 25.82) per ton, while major port prices steadily climbed amid firm holding sentiment among local suppliers. **(Chemical Industry Headlines)**

China Issues Announcement Banning 61 High-Risk Pesticides Nationwide

China's Ministry of Agriculture and Rural Affairs issued Announcement No. 1039, officially publishing a list of 61 completely banned, highly toxic pesticides, including paraquat, methamidophos, and carbofuran. Aimed at safeguarding agricultural quality, public health, and ecological environments, regulatory authorities will strictly penalize any illegal production, sale, or usage of these restricted chemicals nationwide. **(Chemical Industry Headlines)**

China Releases 508 National Standards to Drive Chemical Sector Transformation

China's State Administration for Market Regulation approved 508 national standards, heavily prioritizing the chemical, petrochemical, and new materials sectors. The comprehensive guidelines establish strict water consumption quotas in the Yellow River basin, standardize product carbon footprint accounting, and update safety, rubber, and plastics specifications to accelerate the industry's green, high-quality transition. **(Chemical Industry Headlines)**

China's First Biosimilar For Multiple Sclerosis Launched Domestically

China's National Medical Products Administration has approved a domestically developed biosimilar targeting relapsing forms of multiple sclerosis. Clinical studies demonstrated comparable efficacy and safety to the reference biologic currently on the market. The product is expected to improve affordability and accessibility for patients nationwide. **(National Medical Products Administration)**

China Advances Clinical Trial For Inhaled Gene Therapy Targeting Cystic Fibrosis

A Chinese biotechnology firm has initiated a Phase II clinical trial for an inhaled gene therapy designed to treat cystic fibrosis. Preclinical and early-stage results suggested improved lung function and reduced infection rates in treated subjects. The therapy utilizes a proprietary lipid nanoparticle delivery system optimized for respiratory administration. **(Center for Drug Evaluation)**